Institutional members access full text with Ovid®

Share this article on:

CD117 Immunoreactivity in Atypical Fibroxanthoma

Mathew, Rahel A MD*; Schlauder, Scott M MD†; Calder, Kenneth B MD*; Morgan, Michael B MD*†

American Journal of Dermatopathology: February 2008 - Volume 30 - Issue 1 - pp 34-36
doi: 10.1097/DAD.0b013e31815b8ed5
Original Article

Atypical fibroxanthoma (AFX) is a spindle cell neoplasm of the skin seen typically on sun-damaged skin of the elderly. Though described as a benign entity, local recurrence and distant metastasis have been reported. This study aims to investigate the potential pathogenic role of CD117, the c-kit receptor in AFX. CD117 was detected in 15 of the 16 cases (94%). The percentage of positive cells for CD117 expression among all tumors was approximately 30%. CD117 proved to be a very sensitive marker of AFX. This antibody may be a useful diagnostic adjunct in AFX.

From the *Department of Pathology, University of South Florida College of Medicine; and †Department of Dermatopathology, James A. Haley Veterans Hospital, Tempa, FL.

No financial support was received during preparation of this manuscript. The authors have no conflict of interest with any commercial interests.

Reprints: Dr. Scott M. Schlauder, MD, 12901 Bruce B Downs Boulevard MDC 11, University of South Florida, Department of Pathalogy and Cell Biology, Tempa, FL 33612 (e-mail: sschlaud@health.usf.edu).

© 2008 Lippincott Williams & Wilkins, Inc.